Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial For Brain Peptide PT00114
Portfolio Pulse from Benzinga Newsdesk
Protagenic Therapeutics has initiated a Phase I/IIa clinical trial for PT00114, a synthetic version of the naturally occurring brain peptide TCAP. The trial aims to evaluate the therapeutic potential of PT00114 in treating neuro-psychiatric conditions, including depression, anxiety, and PTSD. The study will recruit 56 subjects and will be managed by Axiom Real-Time Metrics.
September 26, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagenic Therapeutics has initiated a clinical trial for PT00114, which could potentially treat neuro-psychiatric disorders. This could have a positive impact on the company's stock if the trial results are positive.
The initiation of a clinical trial for a potentially groundbreaking treatment could have a positive impact on Protagenic Therapeutics' stock. However, the impact will largely depend on the results of the trial, which are yet to be determined.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100